ABCL - AbCellera Biologics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$8.00
DETAILS
HIGH:
$9.00
LOW:
$7.00
MEDIAN:
$8.00
CONSENSUS:
$8.00
DOWNSIDE:
13.98%
About AbCellera Biologics Inc. (https://www.abcellera.com)
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Carl Hansen | Chief Executive Officer, President & Chairperson | 1975 | $931,152 USD |
| Andrew Booth | Chief Financial Officer | 1974 | $726,811 USD |
| Tryn T. Stimart | Chief Legal Officer, Chief Compliance Officer, Corporate Secretary & Privacy Officer | 1970 | $709,275 USD |
| Veronique Lecault | Chief Technology Officer & Director | 1985 | $681,646 USD |
| Andrew Knowles | Vice President of Operations | – | – |
| Caitlin Webster CIPD | Director of Talent Development | – | – |
| Marcie Thiessen | Senior Director of Finance & Accounting | – | – |
| Martin Hogan | Senior Director of Strategic Finance & IR | – | – |
| Murray McCutcheon | Senior Vice President of Partnering | – | – |
| Tiffany Chiu | Vice President of Communications | – | – |